作者: Edward W. Petrillo
DOI: 10.1002/0471266949.BMC174
关键词: Enzyme inhibitor 、 Angiotensin-converting enzyme 、 Drug 、 Active site 、 Medicine 、 Diabetes mellitus 、 Blood pressure 、 Captopril 、 Heart failure 、 Pharmacology
摘要: The discovery of captopril, the first orally active angiotensin-converting enzyme inhibitor, showed that blockade renin-angiotensin system effectively lowers blood pressure in a wide spectrum patients with hypertension. Captopril was designed using hypothetical model site subsequently guided design new classes inhibitors. Because ACE inhibitors retard progression cardiovascular disease and complications diabetes, leading to an overall reduction mortality, they have become one most widely used drug medicine. New genetic structural evidence has revealed two functional catalytic domains differences may be exploited future superior properties. Keywords: antihypertensive; congestive heart failure; enzyme inhibitor; peptide; reninangiotensin